Event Home
chat
FDA VRBPAC Meeting | May 18th, 2023
*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.
*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.
Agenda The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.
Liveblog provided by Meryl Nass, MD.
